Study on Brentuximab Vedotin with Lenalidomide and Rituximab for Treating Relapsed or Hard-to-Treat Diffuse Large B-Cell Lymphoma

Inclusion Criteria

• Have relapsed or hard-to-treat diffuse large B-cell lymphoma (DLBCL) or transformed DLBCL.
• Have tried at least two previous treatments that did not work.
• Cannot have a stem cell transplant or CAR-T therapy due to medical reasons or other issues like cost or availability.
• Must provide a recent tumor sample for testing.
• Have a performance status score of 0 to 2, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have cancer that shows up on specific scans and is measurable by certain criteria.

Exclusion Criteria

• Have had another cancer within the last two years or still have signs of a previous cancer.
• Have a history of a specific brain disease called progressive multifocal leukoencephalopathy (PML).
• Have active brain or spinal cord disease related to the cancer, unless it has been treated and stable for at least three months.
• Have an uncontrolled severe infection within two weeks before starting the study.
• Have not completed other cancer treatments at least three weeks before starting the study, unless the disease has progressed.
• Have previously been treated with brentuximab vedotin or lenalidomide, unless it was more than six months ago.
• Are currently on certain medications that suppress the immune system or other cancer treatments.
• Have had a recent stroke, heart attack, or severe heart problems within six months before starting the study.
• Have severe heart failure or significant nerve damage.